1. Home
  2. TNON
  3. Earnings

AI Earnings Predictions for Tenon Medical Inc. (TNON)

Machine learning predictions based on historical earnings data and price patterns

Latest Prediction

BUY

1-Day Prediction

+4.86%

$1.88

100% positive prob.

5-Day Prediction

+14.79%

$2.05

100% positive prob.

20-Day Prediction

+6.43%

$1.91

95% positive prob.

Price at prediction: $1.79 Confidence: 100.0% Model AUC: 1.0000 Quarter: Q3 2026

Historical Earnings Predictions

Quarter Signal 1D Return 5D Return 20D Return Confidence Actual 5D
Q3 2026 BUY +4.86% +14.79% +6.43% 100.0% Pending
Q2 2026 SELL -5.50% -9.99% -18.82% 100.0% Pending

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K BUY

Nov 12, 2026 · 100% conf.

AI Prediction BUY

1D

+4.86%

$1.88

Act: -21.23%

5D

+14.79%

$2.05

20D

+6.43%

$1.91

Price: $1.79 Prob +5D: 100% AUC: 1.000
0001213900-26-118946

EX-99.1

2 ea031209601ex99-1.htm

PRESS RELEASE OF TENON MEDICAL, INC., DATED NOVEMBER 12, 2026

Exhibit 99.1

Tenon® Medical Reports Third Quarter 2026 Financial Results

~ Third Quarter 2026 Revenue of $1.4 Million, a 22% Increase Compared to Prior Year ~

~ Third Quarter Gross Profit of $1.0 Million, a 23% Increase Compared to Prior Year; Gross Margin of 66.3% ~

~ Raised Approximately $15.6 Million in Gross Proceeds, Repaid Convertible Notes in Full and Ended the Quarter with $8.3 Million in Cash and Cash Equivalents ~

~ Commenced Full Commercial Launch of 3D-Printed Lateral Screw for the SImmetry®+ SI Joint Fusion System ~

~ Added Eight New U.S. Patents in 2026, Bringing Portfolio to 38 Issued U.S. Patents ~

Los Gatos, CA – November 12, 2026 – Tenon Medical, Inc. (NASDAQ: TNON) (“Tenon Medical” or the “Company”), a company redefining care for patients with sacro-pelvic disorders, today reported financial results for the third quarter ended September 30, 2026.

Financial Results and Business Updates

●Third Quarter 2026 Results:

○Third quarter revenue of $1.4 million, an increase of 22% compared to $1.2 million in the third quarter of 2025.

○Third quarter gross profit of $1.0 million, an increase of 23% compared to $0.8 million in the third quarter of 2025.

○Gross margin of 66.3%, a 0.4 percentage point increase from 65.9% in the third quarter of 2025.

○Cash and cash equivalents of $8.3 million as of September 30, 2026, compared to $3.8 million as of December 31, 2025.

○Operating loss of $3.1 million in the third quarter, an improvement of $0.3 million compared to $3.4 million in the third quarter of 2025.

○Net loss of $6.6 million, or $5.39 per share, in the third quarter of 2026, compared to a net loss of $3.3 million, or $14.17 per share, in the third quarter of 2025.

●Commercially launched the 3D-printed lateral screw for the SImmetry®+ SI Joint Fusion System, the first component of a next-generation lateral system, following an alpha launch that generated approximately $1.2 million in revenue from late in the fourth quarter of 2025 through the third quarter of 2026.

●Raised approximately $15.6 million in aggregate gross proceeds and regained compliance with Nasdaq’s minimum stockholders’ equity requirement. The Company also regained compliance with Nasdaq’s minimum bid price requirement following its 1-for-35 reverse stock split, effective August 10, 2026.

●Repaid in full approximately $5.12 million of remaining principal balance of senior convertible notes ahead of their September 11, 2026 maturity.

Subsequent Updates

●The Company hired Thomas Batton Jr. as Chief Revenue Officer, effective October 1, 2026, to lead the commercial organization. Mr. Batton has over 15 years of medical device sales and commercial leadership experience across spine, neuromodulation and pain management, including extensive experience within SI joint fixation. The Company plans to continue to add to its commercial organization through hiring direct sales representatives and onboarding distributor partners.

●On October 15, 2026, the Company announced that the U.S. Patent and Trademark Office had issued eight new patents to the Company so far in 2026, bringing its portfolio to 38 issued U.S. patents and nine international patents, with 31 U.S. and foreign patent applications pending. The patents include both system and method claims covering the Catamaran® SI Joint Fusion System and are expected to strengthen the Company’s intellectual property position in the sacro-pelvic fusion market.

●On October 28, 2026, the Company announced the completion of the initial alpha cases of its new Quickstep™ Decorticator for the next-generation SImmetry®+ SI Joint Fusion System. Quickstep is designed to streamline joint decortication and simplify the SImmetry+ surgical workflow, and the Company is targeting full market release in the first quarter of 2027.

“Third quarter revenue of $1.4 million grew 22% compared to the prior year and 12% sequentially from the second quarter, and we delivered that growth while reducing operating expenses compared to both the third quarter of 2025 and the second quarter of this year,” said Steven M. Foster, President and CEO of Tenon Medical, Inc. “Just as importantly, we significantly strengthened our balance sheet during the quarter. We raised approximately $15.6 million in aggregate gross proceeds, repaid our convertible notes in full, regained compliance with Nasdaq’s stockholders’ equity and minimum bid price requirements, and ended the quarter with $8.3 million in cash.”

“With our convertible notes now behind us, our attention is fully on growth. The full commercial launch of our 3D-printed SImmetry®+ lateral screw, the first component of our next-generation lateral system, and the completion of initial alpha cases with our Quickstep™ Decorticator, which we are targeting for full market release in the first quarter of 2027, expand the tools we can offer our physician partners. Our eig

2026
Q2

Q2 2026 Earnings

8-K SELL

Aug 13, 2026 · 100% conf.

AI Prediction SELL

1D

-5.50%

$5.63

Act: -13.42%

5D

-9.99%

$5.36

20D

-18.82%

$4.84

Price: $5.96 Prob +5D: 0% AUC: 1.000
0001213900-26-089138

Transcript text not available. View on SEC.gov →

2026
Q1

Q1 2026 Earnings

8-K

May 12, 2026

0001213900-26-055085

Transcript text not available. View on SEC.gov →

About Tenon Medical Inc. (TNON) Earnings

This page provides Tenon Medical Inc. (TNON) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.

Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on TNON's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.

Share on Social Networks: